Fig. 5. The effects of calmidazolium (CMZ) on putative calmodulin-binding domain (CaMBD) (K590-E600)/ΔEF mutants under 16 nM intracellular free calcium concentration. (A) A full current trace (left) and the current (I)–voltage (V) relationship (right) of polycystic kidney disease 2-like-1 (PKD2L1) (K590A/ΔEF) activated by 1 μM of CMZ (blue) under 16 nM free Ca2+. (B) A full current trace (left) and the I–V relationship (right) of PKD2L1 (T591A/ΔEF) activated by 1 μM of CMZ (blue) under 16 nM free Ca2+. (C) A full current trace (left) and the I–V relationship (right) of PKD2L1 (L593A/ΔEF) activated by 1 μM of CMZ (blue) under 16 nM free Ca2+. (D) A summarized basal current amplitude of PKD2L1 (ΔEF) and mutants under 16 nM free Ca2+ (n = 4–6). (E) A summarized CMZ-induced current amplitude of PKD2L1 (ΔEF) and mutants under 16 nM free Ca2+ (n = 4–6). (F) A summarized current changes of PKD2L1 (ΔEF) and mutants by CMZ under 16 nM free Ca2+. *p < 0.05, **p < 0.01.
© Korean J Physiol Pharmacol
